证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2023-003 特定对象调研 □分析师会议 投资者关系活 □媒体采访 业绩说明会 动类别 新闻发布会 □路演活动 现场参观 □其他 （请文字说明其他活动内容） 活动参与人员 民生加银基金管理有限公司、国联安基金管理有限公司、银华基 金管理股份有限公司、农银汇理基金管理有限公司、浙江百年资 产管理有限公司 时间 2023 年 5 月 19 日 地点 成都华神科技集团股份有限公司 形式 ☐现场 ☐网上 电话会议 上市公司接待 李 俊先生（副总裁、财务总监） 人员姓名 刁海雷先生（董事会秘书） 问题 1：今年药品销售收入增长目标？ 答：医药作为核心主业，短期目标是营业收入水平尽快恢复并 超越疫情前收入水平。关于医药业务经营计划方面主要有以下几 交流内容及具 点：（1）持续加大研发投入，对现有重点产品进行二次开发，推 体问答记录 进原有产品"复产复销"；（2）加强招商、丰富产品管线等途径； （3）开展收并购、深度业务合作等方式进行整合存量资源（药品 批文和产品）；（4）持续推进"原料+化学仿制药"一体化项目， 提前 ...

证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2023-002 | | 特定对象调研 □分析师会议 | | | --- | --- | --- | | 投资者关系活 | □媒体采访  业绩说明会 | | | 动类别 | 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 活动参与人员 | 线上参与公司 2022 年度网上业绩说明会的投资者等 | | | 时间 | 年 月 15 日 15:00-17:00 | 2023 5 | | | 同花顺路演平台（网址：https://board.10jqka.com.cn/rs/pc/d | | | 地点 | etail?roadshowId=1005521） | | | 形式 | ☐现场 网上 ☐电话会议 | | | | 黄明良先生（董事长、总裁） | | | 上市公司接待 | 周友苏先生（独立董事） | | | 人员姓名 | 俊先生（副总裁、财务总监） | 李 | | | 刁海雷先生（董事会秘书） 公司以网络远程的方式召开 2022 年度业绩 ...

证券代码：000790 证券简称：华神科技 公告编号：2023-019 成都华神科技集团股份有限公司 关于召开2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、召开时间：2023年5月15日（星期一）15:00-17:00。 2、召开方式：网络互动。 3、出席人员：公司董事长、总裁黄明良先生，独立董事周友苏先生，副总 裁、财务总监李俊先生，董事会秘书刁海雷先生（如遇特殊情况，出席人员将 酌情调整）。 4、投资者参与方式：投资者可以使用电脑端登陆同花顺路演平台进入华神 科技路演厅（https://board.10jqka.com.cn/rs/pc/detail?roadshowId=10055 21）或使用手机从同花顺App端入口（"首页"-搜索-"路演平台"-搜索-"华 神科技"）登陆或使用该App软件扫描下方二维码方式直接登陆，参与本次网上 业绩说明会。 二、公开征集问题 为充分尊重投资者，提高交流效率，现就本次业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可提前登陆同花顺路演平 台，进入公司20 ...

证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2023-001 特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 新闻发布会 □路演活动 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 华宝基金（张金涛）、华安证券（李昌幸）、怀真资产（陈磊）等 时间 2023 年 5 月 9 日 地点 成都华神科技集团股份有限公司 王铎学（董事、副总裁） 【以通讯方式参会】 上市公司接待 李 俊（副总裁、财务总监） 人员姓名 刁海雷（董事会秘书） 问：公司核心产品有哪些？ 答：公司核心产品包括：三七通舒胶囊、鼻渊舒口服液、活力 苏口服液、儿感退热宁口服液、无烟灸条、余甘子喉片、苯溴马隆 胶囊、罗红霉素分散片等 30 余个品种。 投资者关系活 问：关于三七通舒胶囊业务覆盖区域、应用科室？ 动主要内容介 答：三七通舒胶囊业务覆盖全国 30 个省（自治区、直辖市）， 绍 核心销售省区有北京、四川、上海、江苏、山东、湖北等省区，服 务 3000 多家等级医院，科室应用广泛（包括神经内科、脑病科、 内分泌科、肾内科、心血管科、五官 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 220,289,718.39, representing a 6.40% increase compared to CNY 206,595,617.51 in the same period last year[5]. - Net profit attributable to shareholders decreased by 63.00% to CNY 3,209,240.40 from CNY 9,433,788.66 year-on-year[5]. - The total operating revenue for Q1 2023 was CNY 220,289,718.39, an increase of 6.04% compared to CNY 207,039,241.91 in Q1 2022[21]. - The net profit for Q1 2023 was CNY 3,098,819.01, a decrease of 56.5% from CNY 7,132,012.43 in Q1 2022[22]. - The basic and diluted earnings per share for Q1 2023 were both CNY 0.0051, down from CNY 0.0139 in Q1 2022, reflecting a decline in profitability per share[23]. Cash Flow - The cash flow from operating activities showed a significant decline of 645.24%, resulting in a net outflow of CNY 119,963,874.13 compared to a net inflow of CNY 19,660,473.69 in the previous year[5]. - Cash inflow from operating activities totaled 140,610,550.26, down from 227,591,626.13, representing a decrease of approximately 38.3%[24]. - Cash outflow from operating activities increased to 260,574,424.39 from 205,589,514.05, marking an increase of about 26.7%[24]. - The net cash flow from operating activities was -119,963,874.13, a significant decline compared to 22,002,112.08 in the previous period[24]. - The net cash flow from investing activities was -41,959,403.22, an improvement from -193,328,707.98 in the previous period[25]. - Total cash inflow from financing activities reached 263,834,018.63, a substantial increase from 28,020,000.00[25]. - The net cash flow from financing activities was 228,454,523.64, compared to 27,659,959.66 previously, indicating a significant increase[25]. Assets and Liabilities - Total assets increased by 15.91% to CNY 1,943,849,980.16 from CNY 1,677,058,446.16 at the end of the previous year[5]. - The total current assets increased to ¥1,028,022,488.01 from ¥784,306,279.15, reflecting a growth of 31.1%[17]. - The total liabilities rose to CNY 900,538,882.81 in Q1 2023, up from CNY 671,561,352.92 in Q1 2022, indicating an increase of 34.06%[19]. - The company's long-term investments increased to CNY 55,604,898.43 in Q1 2023, compared to CNY 14,519,833.30 in Q1 2022, showing a strategic focus on long-term growth[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 47,722[12]. - The largest shareholder, Sichuan Huashen Group, holds 111,431,281 shares, accounting for 17.74% of total shares[12]. - The company has 269,460 restricted stocks released for trading as of January 3, 2023, following the first phase of its stock incentive plan[14]. - The company repurchased and canceled 431,000 restricted stocks due to the departure of four incentive plan participants[14]. Operational Changes - The company completed a controlling acquisition of Shandong Lingkai Pharmaceutical Co., Ltd., increasing its stake from 49% to 70%[15]. - The company plans to establish Shandong Lingkai as a CDMO and synthetic biology production base, enhancing its competitive edge in the industry[15]. Other Financial Metrics - The weighted average return on equity decreased to 0.32% from 0.96% in the previous year[5]. - The company's cash and cash equivalents increased to ¥244,209,509.01 from ¥144,637,734.98 at the beginning of the year, representing a growth of 68.9%[17]. - Accounts receivable decreased slightly to ¥410,957,042.61 from ¥412,729,958.09, showing a decrease of 0.4%[17]. - The company has a total of 54,109,956.51 in other receivables, up from 28,123,081.88, indicating a growth of 92.6%[17]. - The company's cash outflow from investing activities decreased by 76.28% to CNY 46,911,431.72, mainly due to reduced payments for investments in new subsidiaries[11]. - The company reported a cash inflow of 4,952,028.50 from investment activities, slightly up from 4,466,000.00[25].

Financial Performance - The company's operating revenue for 2022 was CNY 873,103,022.86, a decrease of 8.55% compared to CNY 945,317,490.17 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 41,217,518.38, down 25.91% from CNY 70,321,594.57 in the previous year[20]. - The basic earnings per share for 2022 was CNY 0.07, a decrease of 22.22% compared to CNY 0.11 in 2021[20]. - The weighted average return on net assets for 2022 was 4.15%, down from 7.45% in 2021[20]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which was CNY 38,235,775.09, down 33.49% from CNY 70,286,853.72 in 2021[20]. - The company achieved operating revenue of CNY 873.10 million in the reporting period, a decrease of 8.55% year-on-year[48]. - The net profit attributable to shareholders was CNY 41.22 million, a decline of 25.91% compared to the previous year, primarily due to decreased sales volume and increased stock incentive expenses[48]. - The pharmaceutical manufacturing business generated revenue of CNY 421.92 million, down 15.29% due to reduced hospital visits and medication demand influenced by policy changes[48]. - The health and wellness business saw a significant increase in revenue to CNY 121,204,679.37, representing a growth of 1,089.20% compared to CNY 10,192,140.12 in 2021[56]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to CNY 155,887,751.05, a 346.68% increase from a negative cash flow of CNY -55,640,088.39 in 2021[20]. - The company reported a net cash flow from financing activities of CNY 85,854,184.18, an increase of 65.24% year-on-year, primarily due to new bank loans and restricted stock incentive funding[69]. - The company’s investment activities resulted in a net cash outflow of CNY 477,813,688.38, a significant increase of 408.72% compared to the previous year[69]. - The total investment amount for the reporting period reached CNY 482,391,129.83, representing a significant increase of 317.29% compared to the previous year[75]. - The company made a major equity investment of CNY 190,000,000.00 in a pharmaceutical research and development firm, acquiring a 5.71% stake[76]. - The company also invested CNY 55,725,500.00 for a 49.00% stake in another pharmaceutical company during the reporting period[76]. Market Position and Product Development - The company is recognized as a national high-tech enterprise and has established a nationwide marketing service network for pharmaceuticals[35]. - The core product "Sanqi Tongshu Capsule" ranks among the top in sales in the oral traditional Chinese medicine market for cerebrovascular diseases in urban public hospitals[35]. - The company has 26 registered drug production varieties, including 17 traditional Chinese medicine products and 8 chemical drug products, with 5 varieties included in the national essential drug list[40]. - The core product, Sanqi Tongshu Capsule, has been recognized as a national second-class new drug and has a significant market presence in the cardiovascular field, covering over 4,000 medical institutions across 28 provinces[40]. - The company is actively investing in CDMO and synthetic biology industries to align with its modernization of traditional Chinese medicine strategy[43]. - The company is advancing the development of the "Sanqi Tongshu Capsule" to expand its market applications and enhance its clinical value, aiming for international development and improved competitiveness[66]. - The company is also working on the "Biyuan Shuqing Oral Liquid" project, focusing on clinical advantages and market value, with plans to enhance product quality and expand market sales[66]. Research and Development - Research and development (R&D) investment amounted to CNY 25,176,903.59, representing a year-on-year increase of 34.26% and accounting for 2.88% of operating revenue[68]. - The number of R&D personnel increased slightly to 138, with a decrease in the proportion of R&D staff from 21.17% in 2021 to 15.35% in 2022[68]. - The company completed 13 new patent applications and received 11 patent grants, enhancing its intellectual property portfolio[52]. - The company holds a total of 144 patents, with 125 granted, including 4 international invention patents, showcasing its strong focus on R&D and innovation[45]. Corporate Governance and Management - The company maintains independent operations in business, personnel, assets, and finance, ensuring no reliance on controlling shareholders for operational activities[107]. - The company has a complete production and operational system, with clear ownership of major assets related to production and operation[111]. - The company has established a robust internal management structure that operates independently, ensuring no mixed operations with controlling shareholders[112]. - The company has implemented stock incentive plans for its executives, indicating a commitment to aligning management interests with shareholder value[118]. - The company’s governance structure includes independent directors, which supports transparency and accountability in decision-making[120]. - The company has a diverse board composition, including both male and female directors[130]. Environmental Responsibility - The company strictly adheres to multiple environmental protection laws and standards, ensuring compliance in its operations[164]. - The company has achieved compliance in wastewater discharge, with all monitored pollutants meeting regulatory standards[165]. - The company has established a comprehensive wastewater treatment system and six related waste gas collection systems, all of which are operating normally and meeting discharge standards[171]. - The company has implemented an emergency response plan for environmental incidents, including regular drills to enhance employee awareness and response capabilities[170]. - The company received recognition as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for the years 2019, 2020, and 2021[173][174][175]. Social Responsibility - The company has emphasized its social responsibility by actively participating in public welfare and educational support initiatives[177]. - The company donated RMB 100,000 to the Hainan Youth Hope Foundation in August 2022 to support pandemic prevention efforts in Hainan, earning the title of "Anti-epidemic Caring Unit" in Hainan[177]. - The company has committed to maintaining a neutral position in business operations to ensure fair competition among its subsidiaries[181]. Future Outlook - The company provided guidance for 2023, expecting revenue growth of 10% to 12%, projecting total revenue between CNY 1.65 billion and CNY 1.68 billion[126]. - New product launches are anticipated to contribute an additional CNY 300 million in revenue in 2023, focusing on innovative biotechnology solutions[126]. - The company plans to enhance its CDMO/synthetic biology production base in Shandong, with a focus on project completion and revenue generation[95]. - The company aims to establish a comprehensive health product ecosystem to enhance service quality and market competitiveness[95].

证券代码：000790 证券简称：华神集团 编号：2014-003 成都华神集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 利安资金管理蔡树荣，摩根大通谢舒莹、李丽丽 | | 人员姓名 | 2014.7.15 | | | 时间 | | | | 地点 | 公司会议室 | | | 上市公司接待人 | 曾云莎、刘渝灿 | | | 员姓名 | | | | 投资者关系活动 | | 现场会议座谈了解公司基本情况，未提供书面资料。 | | 主要内容介绍 | | 一、请介绍一下贵公司所生产的 ...

证券代码：000790 证券简称：华神集团 编号：2015-001 成都华神集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安信证券 吴永强 | | | 人员姓名 | 湘财证券 罗定伟 | | | 时间 | 2015.1.23 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 周蕴瑾、曾云莎 | | | 员姓名 | | | | 投资者关系活动 | | 现场会议座谈了解公司基本情况，未提供书面资料。 | | 主要内容介绍 | | 一、利卡汀中心运营情况？利卡汀中心是否可以延展医疗 | | | | 服 ...